bisbenzimidazole has been researched along with u 0126 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cavanaugh, J; Chopra, I; Flaherty, PT; Jain, P; Monlish, D | 1 |
Cui, C; Ding, HF; Fan, Y; Fu, SB; Jiang, LH; Li, J; Ma, L; Sun, DJ; Yang, J; Zhang, YN | 1 |
2 other study(ies) available for bisbenzimidazole and u 0126
Article | Year |
---|---|
Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway.
Topics: Benzimidazoles; Epidermal Growth Factor; HEK293 Cells; Humans; Mitogen-Activated Protein Kinase 7; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship | 2010 |
The Raf-1 inhibitor GW5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine.
Topics: Apoptosis; Bisbenzimidazole; Blotting, Western; Butadienes; Cell Survival; Enzyme Inhibitors; Flow Cytometry; Humans; Indicators and Reagents; Indoles; MAP Kinase Signaling System; Nitriles; Oxidopamine; Parkinson Disease; PC12 Cells; Phenols; Phosphorylation; Proto-Oncogene Proteins c-raf | 2012 |